Package leaflet: Information for the patient

Levetiracetam Hexal 250 mg, filmomhulde tabletten
Levetiracetam Hexal 500 mg, filmomhulde tabletten
Levetiracetam Hexal 750 mg, filmomhuldetabletten
Levetiracetam Hexal 1000 mg, filmomhulde tabletten

levetiracetam

Read all of this leaflet carefully before you or your child start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What [Nationally completed name] is and what it is used for

Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).
[Nationally completed name] is used:
- on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.

- as an add-on to other antiepileptic medicines to treat :
  - partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age;
  - myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;

- primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

2. What you need to know before you take [nationally completed name]

Do not take [nationally completed name]

- if you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in Section 6).

Warnings and precautions

Talk to your doctor before taking [nationally completed name]

- If you suffer from kidney problems, follow your doctor's instructions. He/she may decide if your dose should be adjusted. [Nationally completed name] 1500 mg is not suitable for the treatment of patients with renal impairment.
- If you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor.
- A small number of people being treated with antiepileptics such as [nationally completed name] have had thoughts of harming or killing themselves. If you have any symptoms of depression and / or suicidal ideation, please contact your doctor.
- If you have a family or medical history of irregular heart rhythm (visible on an electrocardiogram), or if you have a disease and/or take a treatment that make(s) you prone to heartbeat irregularities or salt imbalances.

Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:

- Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour.
- Aggravation of epilepsy
  Your seizures may rarely become worse or happen more often, mainly during the first month after the start of the treatment or increase of the dose.
  In a very rare form of early-onset epilepsy (epilepsy associated with SCN8A mutations) that causes multiple types of seizures and loss of skills you may notice that the seizures remain present or are becoming worse during your treatment

  If you experience any of these new symptoms while taking [nationally completed name], see a doctor as soon as possible.

Children and adolescents

- [Nationally completed name] is not indicated in children and adolescents below 16 years on its own (monotherapy).
- [Nationally completed name] 1500 mg is not indicated in children and adolescents below 16 years on its own (monotherapy) or any weighing less than 50 kg.

Other medicines and [Nationally completed name]

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a loss of its effect.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. [Nationally completed name] can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor.
You should not stop your treatment without discussing this with your doctor. A risk of birth defects for your unborn child cannot be completely excluded. Two studies do not suggest an increased risk of autism or intellectual disability in children born to mothers treated with levetiracetam during pregnancy. However, the available data regarding the impact of levetiracetam on neurodevelopment in children is limited.
Breast-feeding is not recommended during treatment.

Driving and using machines

[Nationally completed name] may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.

[NL/H/2151-2152-2153-2155/001-004]
[Nationally completed name] contains sodium
[Nationally completed name] contains less than 1 mmol sodium (23mg) per film-coated tablet, that is to say essentially ‘sodium-free’.

3. How to take [nationally completed name]

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Take the number of tablets following your doctor's instructions.
[Nationally completed name] must be taken twice a day, once in the morning and once in the evening, at about the same time each day.

[Nationally completed name] 1500 mg is not suitable for therapy initiation, for dose adjustments or for gradually withdrawal. [Nationally completed name] 1500 mg is not available in all pharmaceutical forms described below. For these dose and pharmaceutical forms, particularly for starting dose and dose adjustments other medicines containing levetiracetam should be used.

Adjunctive Therapy and monotherapy (from 16 years of age)

- **Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more:**

Recommended dose: between 1,000 mg and 3,000 mg each day.
When you will first start taking [nationally completed name], your doctor will prescribe you a **lower dose** during 2 weeks before giving you the lowest daily dose.
Example: if your daily dose is intended to be 1,000 mg, your reduced starting dose is 1 tablet of 250 mg in the morning and 1 tablet of 250 mg in the evening, and the dose will be gradually incremented to reach 1000 mg daily after 2 weeks.

- **Adolescents (12 to 17 years) weighing 50 kg or less:**
  Your doctor will prescribe the most appropriate pharmaceutical form of [nationally completed name] according to weight and dose.

- **Dose in children (6 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:**

[Nationally completed name] 1500 mg is not suitable for the treatment of children and adolescents weighing less than 50 kg.

- **Dose in infants (1 month to 23 months) and children (2 to 11 years) weighing less than 50 kg**
  Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to the age, weight and dose.

  Levetiracetam 100 mg/ml oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescents (from 6 to 17 years) weighing less than 50kg and when tablets don't allow accurate dosage.

Method of administration
Swallow [nationally completed name] tablets with a sufficient quantity of liquid (*e.g.* a glass of water).
You may take [nationally completed name] with or without food.
After oral administration the bitter taste of levetiracetam may be experienced.
The tablet can be divided into equal doses.

Duration of treatment

- [Nationally completed name] is used as a chronic treatment. You should continue the treatment for as long as your doctor has told you.
- Do not stop your treatment without your doctor's advice as this could increase your seizures.

If you take more [nationally completed name] than you should
The possible side effects of an overdose of [nationally completed name] are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Contact your doctor if you took more tablets than you should. Your doctor will establish the best possible treatment of overdose.

If you forget to take [nationally completed name]
Contact your doctor if you have missed one or more doses.
Do not take a double dose to make up for a forgotten tablet.

If you stop taking [nationally completed name]
If stopping treatment, [nationally completed name] should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your [Nationally completed name] treatment, he/she will instruct you about the gradual withdrawal of [Nationally completed name].

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor immediately, or go to your nearest emergency department, if you experience:
- weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction
- swelling of the face, lips, tongue and throat (Quincke's oedema)
- flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia), enlarged lymph nodes and the involvement of other body organs (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]).
- symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function
- a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)
- a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)
- a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis)
- signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour

or other neurological signs including involuntary or uncontrolled movements). These could be symptoms of an encephalopathy.

The most frequently reported side effects are nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.

Very common: may affect more than 1 in 10 people
- nasopharyngitis;
- somnolence (sleepiness), headache.

Common: may affect up to 1 in 10 people
- anorexia (loss of appetite);
- depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
- convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
- vertigo (sensation of rotation);
- cough;
- abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;
- rash;
- asthenia/fatigue (tiredness).

Uncommon: may affect up to 1 in 100 people
- decreased number of blood platelets, decreased number of white blood cells;
- weight decrease, weight increase;
- suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;
- amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
- diplopia (double vision), vision blurred;
- elevated/abnormal values in a liver function test;
- hair loss, eczema, pruritus;
- muscle weakness, myalgia (muscle pain);
- injury.

Rare: may affect up to 1 in 1,000 people
- infection;
- decreased number of all blood cell types;
- severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke’s oedema [swelling of the face, lips, tongue and throat]);
- decreased blood sodium concentration;

- suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);
- delirium;
- encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of symptoms);
- seizures may become worse or happen more often;
- uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);
- change of the heart rhythm (Electrocardiogram);
- pancreatitis;
- liver failure, hepatitis;
- sudden decrease in kidney function;
- skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens– Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis);
- rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients;
- limp or difficulty walking;
- combination of fever, muscle stiffness, unstable blood pressure and heart rate, confusion, low level of consciousness (may be signs of a disorder called *neuroleptic malignant syndrome*). Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.

Very rare: may affect up to 1 in 10000 people
- repeated unwanted thoughts or sensations or the urge to do something over and over again (Obsessive Compulsive Disorder).

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store [nationally completed name]

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton box/bottle and blister after “EXP”.
The expiry date refers to the last day of the month.

[NL/H/2151-2152-2153-2155/001-004]
Store in the original package in order to protect from moisture.
[NL/H/2155/005]
This medicine does not require any special storage conditions.

The shelf life after first opening of the bottle is 100 days.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What [Nationally completed name] contains

- The active substance is levetiracetam.
  Each film-coated tablet contains 250 mg of levetiracetam.
  Each film-coated tablet contains 500 mg of levetiracetam.
  Each film-coated tablet contains 750 mg of levetiracetam.
  Each film-coated tablet contains 1000 mg of levetiracetam.
  Each film-coated tablet contains 1500 mg of levetiracetam.

250 mg film-coated tablets:

NL/H/2151-2155
- The other ingredients are povidone K25, microcrystalline cellulose, croscarmellose sodium, crospovidone (type A), silica colloidal anhydrous, talc, magnesium stearate, hypromellose, hydroxypropylcellulose, macrogol type 6000, titanium dioxide (E 171), talc, indigo carmine (E 132) (contains sodium).

NL/H/2152-2153
- The other ingredients are povidone K25, microcrystalline cellulose, croscarmellose sodium, crospovidone (type A), silica colloidal anhydrous, talc, magnesium stearate, hypromellose, hydroxypropylcellulose, macrogol type 6000, titanium dioxide (E 171), talc, indigo carmine aluminium lake (E 132).

500 mg film-coated tablets:
- The other ingredients are povidone K25, microcrystalline cellulose, croscarmellose sodium, crospovidone (type A), silica colloidal anhydrous, talc, magnesium stearate, hypromellose, hydroxypropylcellulose, macrogol type 6000, titanium dioxide (E 171), talc, iron oxide yellow (E 172).

750 mg film-coated tablets:

- The other ingredients are povidone K25, microcrystalline cellulose, croscarmellose sodium, crospovidone (type A), silica colloidal anhydrous, talc, magnesium stearate, hypromellose, hydroxypropylcellulose, macrogol type 6000, titanium dioxide (E 171), talc, iron oxide red (E 172), iron oxide yellow (E 172).

1000 mg film-coated tablets:
The other ingredients are povidone K25, microcrystalline cellulose, croscarmellose sodium, crospovidone (type A), silica colloidal anhydrous, talc, magnesium stearate, hypromellose, hydroxypropylcellulose, macrogol type 6000, titanium dioxide (E 171), talc.

1500 mg film-coated tablets:
The other ingredients are crospovidone Type A, crospovidone Type B, povidone K30, silica colloidal anhydrous, magnesium stearate, hypromellose, titanium dioxide (E 171), talc, macrogol 400, iron oxide yellow (E 172), indigo carmine aluminium lake (E 132).

What [nationally completed name] looks like and contents of the pack

250 mg film-coated tablets:
Light blue, oval, biconvex film-coated tablets, scored on both sides, debossed with ‘LVT / 250’ on one side.
500 mg film-coated tablets:
Yellow, oval, biconvex film-coated tablets, scored on both sides, debossed with ‘LVT / 500’ on one side.

750 mg film-coated tablets:
Apricot color, oval, biconvex film-coated tablets, scored on both sides, debossed with ‘LVT / 750’ on one side.

1000 mg film-coated tablets:
White, oval, biconvex film-coated tablets, scored on both sides, debossed with ‘LVT / 1000’ on one side.

1500 mg film-coated tablets:
Green, oval shaped, film-coated tablets, scored on one side.

[NL/H/2151-2152-2153-2155/001-004]
The film-coated tablets are packed in OPA/Alu/PVC-Alu blisters or HDPE bottles with polypropylene screw cap and silicagel capsule and inserted in a carton.

[NL/H/2155/005]
The film-coated tablets are packaged in Aluminium-PVC/PE/PVDC blisters placed into cardboard boxes.

[NL/H/2151/001]
Pack sizes:
Blister: 10, 20, 28, 30, 50, 50×1, 60, 100, 120, 200 film-coated tablets
Bottle: 10, 20, 30, 50, 60, 100, 120, 200 film-coated tablets

[NL/H/2151/002-004]
Pack sizes:
Blister: 10, 28, 30, 50, 50×1, 60, 100, 120, 200 film-coated tablets
Bottle: 10, 20, 30, 50, 60, 100, 120, 200 film-coated tablets

[NL/H/2152]
Pack sizes:
Blister: 10, 20, 50, 100, 200 film-coated tablets
Bottle: 10, 20, 30, 50, 60, 100, 120, 200 film-coated tablets

[NL/H/2153]
Pack sizes:
Blister: 10, 20, 30, 50, 60, 100, 200 film-coated tablets
Bottle: 10, 20, 30, 50, 60, 100, 120, 200 film-coated tablets

[NL/H/2155/001]
Pack sizes:
Blister: 10, 20, 30, 50, 60, 100, 200 film-coated tablets
Bottle: 10, 20, 30, 50, 60, 100, 120, 200 film-coated tablets

[NL/H/2155/002]
Pack sizes:
Blister: 10, 20, 30, 50, 60, 100, 120, 200 film-coated tablets
Bottle: 10, 20, 30, 50, 60, 100, 120, 200 film-coated tablets

[NL/H/2155/003]
Pack sizes:
Blister: 10, 30, 50, 60, 100 film-coated tablets
Bottle: 10, 20, 30, 50, 60, 100, 120, 200 film-coated tablets

[NL/H/2155/004]
Pack sizes:
Blister: 10, 20, 30, 50, 60, 100, 200 film-coated tablets
Bottle: 10, 20, 30, 50, 60, 100, 120, 200 film-coated tablets

[NL/H/2155/005]
Pack sizes:

30, 50, 60 and 100 film-coated tablets

Not all pack sizes may be marketed.

Houder van de vergunning voor het in de handel brengen en fabrikant
Vergunninghouder en Fabrikant:
HEXAL AG
Industriestrasse 25
83607 Holzkirchen
Duitsland

Manufacturer
Lek Pharmaceuticals d.d.
Verovškova 57
1526 Ljubljana
Slovenië

LEK S.A.
Ul. Domaniewska 50 C
02-672 Warschau
Polen

Salutas Pharma GmbH
Otto-von-Guericke Allee 1
39179 Barleben
Duitsland

S.C. Sandoz, S.R.L.
Str. Livezeni nr. 7A
RO-540472 Targu-Mures
Roemenië

Lek Pharmaceuticals d.d.
Trimlini 2 D
9220 Lendava
Slovenië

In het register ingeschreven onder:
Levetiracetam Hexal 250 mg, filmomhulde tabletten: RVG 108534
Levetiracetam Hexal 500 mg, filmomhulde tabletten: RVG 108537
Levetiracetam Hexal 750 mg, filmomhulde tabletten: RVG 108538
Levetiracetam Hexal 1000 mg, filmomhulde tabletten: RVG 108539

Dit medicijn is geregistreerd in lidstaten van de Europese Economische Ruimte onder de volgende namen:

Nederland: Levetiracetam Hexal 250, 500, 750, 1000 mg, filmomhulde tabletten
Duitsland: Levetiracetam HEXAL 250, 500, 750, 1000 mg Filmtabletten

Deze bijsluiter is voor het laatst goedgekeurd in oktober 2025